97048 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
MODIFIED LIGAND-GATED ION CHANNELS AND METHODS OF USE
#2GENETICALLY ENCODED BIOLUMINESCENT SENSORS
#3COMPOSITIONS AND METHODS OF ACETYCHOLINE RECEPTOR CHIMERIC AUTOANTIBODY RECEPTOR CELLS
#4PROTEINS COMPRISING THE EXTRACELLULAR DOMAIN OF P75NTR
#5METHODS OF DIAGNOSING, DETERMINING THE PROGRESSION OF, AND TREATING A PROSTATE CANCER
#6REAGENT, PHARMACEUTICAL COMPOSITION AND METHODS FOR DETECTING, EVALUATING THE PROGRESSION, AND TREATING DISEASES ASSOCIATED WITH B-AMYLOID PLAQUES
#7EXPRESSION SYSTEMS FOR THE ALPHA2ALPHA5BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR AND METHODS OF USE THEREOF
#8EXPRESSION SYSTEMS FOR THE ALPHA6-CONTAINING NICOTINIC ACETYLCHOLINE RECEPTOR AND METHODS OF USE THEREOF
#9Binding Domains Directed Against GPCR:G Protein Complexes and Uses Derived Thereof
#10LIGAND GATED ION CHANNELS AND METHODS OF USE
#11MODIFIED LIGAND-GATED ION CHANNELS AND METHODS OF USE
#12Membrane fusion proteins
#13IG-LIKE FUSION PROTEINS AND USE THEREOF
#14CSF TRANSPORT PATHWAY FOR DELIVERY OF AGENTS TO INNER EAR
#15TRANSGENE CASSETTES, AAV VECTORS AND AAV VIRAL VECTORS FOR THE EXPRESSION OF HUMAN CODON-OPTIMIZED SLC6A1
#16Neurotensin Variants And Tagged Proteins Comprising Neurotensin Or Sortilin Propeptide
#17COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES
#18SORLA MINI-RECEPTOR FOR TREATMENT OF ALZHEIMER'S DISEASE
#19EXOSOME PACKAGING AND TARGETED AUTOPHAGY
#20SYSTEMS AND METHODS FOR DELIVERY OF SPADIN FOR TREATMENT OF DEPRESSION OR OTHER INDICATIONS
#21FUSION PROTEIN FOR TREATING MYASTHENIA GRAVIS
#22GENE CODING FOR CHIMERIC RECEPTOR FOR ANTI-ACETYLCHOLINE RECEPTOR AUTOANTIBODY
#23SYSTEMS AND METHODS FOR PROTEIN EXPRESSION
#24GENE THERAPY FOR DOPAMINE TRANSPORTER DEFICIENCY SYNDROME
#25SYSTEM AND METHOD FOR HOMOGENOUS GPCR PHOSPHORYLATION AND IDENTIFICATION OF BETA-2 ADRENERGIC RECEPTOR POSITIVE ALLOSTERIC MODULATORS
#26COMPOSITIONS AND METHODS OF INHIBITING THE BINDING OF PLASMA IGG AUTOANTIBODIES TO SEROTONIN 2A RECEPTOR
#27COMPOUND FOR THE PREVENTION OR TREATMENT OF MYASTHENIA GRAVIS
#28Nucleic Acid Constructs, Viral Vectors and Viral Particles
#29COMPOUND FOR THE PREVENTION OR TREATMENT OF AUTOANTIBODY-MEDIATED CONDITIONS
#30SYSTEMS AND METHODS FOR ENHANCED IMMUNOTHERAPIES
#31MODIFIED MGLUR6 PROMOTER AND METHODS OF USE
#32NMDA RECEPTOR CONSTRUCTS TO DETECT AND ISOLATE NMDAR AUTOANTIBODIES
#33A DRUG SCREENING PLATFORM FOR ENDOSOMAL ENHANCERS TO TREAT ALZHEIMER'S DISEASE
#34ARTIFICIAL EXCITATORY SYNAPSE CONNECTOR AND USE THEREOF FOR SPINAL CORD INJURY
#35DOPAMINE D2 RECEPTOR LIGANDS
#36THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN
#37PLASMIN-RESISTANT PEPTIDES FOR TREATING STROKE AND RELATED CONDITIONS
#38SORTILIN BINDING CONJUGATE COMPOUNDS, COMPOSITIONS AND USES THEREOF FOR TREATING CANCER
#39MUTANT PROTEINS AND METHODS FOR THEIR PRODUCTION
#40CHIMERIC RECEPTOR SENSORS
#41COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES
#42EXPRESSION OF NEUROPEPTIDES
#43SORCS2 CRYSTAL STRUCTURE AND USES THEREOF
#44COMPOSITIONS AND METHODS OF ACETYLCHOLINE RECEPTOR CHIMERIC AUTOANTIBODY RECEPTOR CELLS
#45THERAPY FOR SUBARACHNOID HEMORRHAGE AND ISCHEMIA
#46Methods of diagnosing, determining the progression of, and treating a prostate cancer
#47LYOPHILIZED FORMULATION OF TAT-NR2B9C WITH ACETYLATION SCAVENGER
#48GPR156 Variants And Uses Thereof
#49MODIFIED LIGAND-GATED ION CHANNELS AND METHODS OF USE
#50Compositions Comprising Sortilin-1
#51MODIFIED LIGAND-GATED ION CHANNELS AND METHODS OF USE
#52Allele specific modulators of P23H rhodopsin
#53SCREENING METHOD FOR THERAPEUTIC DRUG OR PROPHYLACTIC DRUG FOR TAUOPATHY AND DIAGNOSTIC METHOD FOR TAUOPATHY
#54DESIGN AND DEVELOPMENT OF NEUROKININ-1 RECEPTOR-BINDING AGENT DELIVERY CONJUGATES
#55Modified ligand-gated ion channels and methods of use
#56EXOSOME PACKAGING AND TARGETED AUTOPHAGY
#57METHODS FOR SCREENING FOR BINDING PARTNERS OF G-PROTEIN COUPLED RECEPTORS
#58Dopamine D2 receptor ligands
#59COMPOSITIONS AND METHODS FOR ENHANCING ODORANT RECEPTOR ACTIVITY
#60Transgene cassettes, AAV vectors and AAV viral vectors for the expression of human codon-optimized SLC6A1
#61PEPTIDES
#62Red fluorescent protein-based biosensor for measuring activity of dopamine receptor D1
#63METHODS FOR CELL-TYPE SPECIFIC PROFILING TO IDENTIFY DRUG TARGETS
#64Anti-fungal inhibitors
#65Methods for quantifying ligand efficacy in G-protein coupled receptors using single-molecule fluorescence energy transfer
#66COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES
#67FUSION POLYPEPTIDE
#68Modified ligand-gated ion channels and methods of use
#69Expression systems and methods of use thereof
#70Diagnosis and therapy of multiple sclerosis
#71POSITIVE ALLOSTERIC MODULATORS OF GABA A RECEPTOR
#72Binding domains directed against GPCR:G protein complexes and uses derived thereof
#73Compositions comprising G protein-coupled receptors maintained in a conformationally selective manner by a modulator
#74GPR156 variants and uses thereof
#75Model for high-throughput screening of endocrine disruptor and method for screening same
#76MUTANT PROTEINS AND METHODS FOR THEIR PRODUCTION
#77Butane-tetraol-based amphiphiles and uses thereof
#78Therapy for subarachnoid hemorrhage and ischemia
#79Modified mGluR6 promoter and methods of use
#80Allele specific modulators of P23H rhodopsin
#81DOPAMINE RECEPTOR TYPE 2 SPECIFIC PROMOTER AND METHODS OF USE THEREOF
#82OR10H1 ANTIGEN BINDING PROTEINS AND USES THEREOF
#83Modified ligand-gated ion channels and methods of use
#84Method of Identifying Transmembrane Protein-interacting Compounds
#85Somatic opsins for single cell resolution optogenetics
#86IMMUNE MODULATORS FOR REDUCING IMMUNE-RESISTANCE IN MELANOMA AND OTHER PROLIFERATIVE DISEASES
#87System and method for homogenous GPCR phosphorylation and identification of beta-2 adrenergic receptor positive allosteric modulators
#88LYOPHILIZED FORMULATION OF TAT-NR2B9C WITH ACETYLATION SCAVENGER
#89VACCINES FOR PREVENTING MENINGOCOCCAL INFECTIONS
#90GPR156 variants and uses thereof
#91Compounds for the treatment of neuromuscular disorders
#92Modified ligand-gated ion channels and methods of use
#93Combined use of a vector encoding a modified receptor and its exogenous agonist in the treatment of seizures
#94Expression of neuropeptides
#95METHODS FOR SCREENING FOR BINDING PARTNERS OF G-PROTEIN COUPLED RECEPTORS
#96Method and composition for treating neuronal hyper-excitabtiity
#97USE OF DESIGNER RECEPTORS EXCLUSIVELY ACTIVATED BY DESIGNER DRUGS AND ULTRASOUND IN THE TREATMENT OF SEIZURE DISORDERS
#98TRANSGENIC MICE
#99Targeted expression of chloride channels and methods of use thereof
#100Compositions and methods for enhancing odorant receptor activity
#101Anti-human ADRB3 monoclonal antibody and application thereof in disease diagnosis and treatment
#102ANTI-HLA ASSAY AND METHODS
#103Mutant proteins and methods for their production
#104Method of Identifying Transmembrane Protein-interacting Compounds
#105Radiolabelled mGluR2 PET ligands
#106MODIFIED T CELLS AND THEIR USES IN TREATING CANCER
#107Allele specific modulators of P23H rhodopsin
#108COMPOSITIONS AND METHODS FOR NEURONAL DIFFERENTIATION OF CELLS
#109Dopamine D2 receptor ligands
#110Method for selecting odor-controlling substance
#111Methods for detecting prostate cancer by determining the ratio of early to late endosomal markers
#112PEPTIDES THAT MODULATE THE EFFECT OF THE CRMP: NEUROFIBROMIN COMPLEX ON SYNAPTIC TRANSMISSION
#113Complexes comprising transmembrane receptors and antibodies that bind the receptors in a conformationally selective manner
#114METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PANCREATIC CANCER
#115Methods for the determination of the biological activities of neurotoxin polypeptides
#116VACCINES FOR PREVENTING MENINGOCOCCAL INFECTIONS
#117GPR156 variants and uses thereof
#118Modified ligand-gated ion channels and methods of use
#119Method of Identifying Transmembrane Protein-interacting Compounds
#120Dopamine receptor type 2 specific promoter and methods of use thereof
#121Compositions and methods for enhancing odorant receptor activity
#122Binding domains directed against GPCR:G protein complexes and uses derived thereof
#123Chimeric antigen receptors
#124Lysosomal targeting and uses thereof
#125Development of neurokinin-1 receptor-binding agent delivery conjugates
#126Therapeutic use of p75NTR neurotrophin binding protein
#127NOGO Receptor-Mediated Blockade of Axonal Growth
#128Lyophilized formulation of TAT-NR2B9C with acetylation scavenger
#129Mammalian cell lines expressing functional nematode acetylcholine receptors and use thereof for high-throughput screening assays
#130METHOD FOR DIAGNOSING AND MONITORING THE PRESENCE OF CANCER IN A HUMAN SUBJECT
#131Muller cell-specific promoter
#132Synthesis of amphiphilic calixarene glycoside detergents and use of same for extracting and stabilizing native functional membrane proteins
#133Modified MGLUR6 promoter and methods of use
#134Diagnosis and therapy of multiple sclerosis
#135Combined use of a vector encoding a modified receptor and its exogenous agonist in the treatment of seizures
#136Capsid-mutated rAAV vectors and methods of use
#137System and method for controlling G-protein coupled receptor pathways
#138Methods for screening for binding partners of G-protein coupled receptors
#139Nucleic acids encoding polypeptides which disrupt D1-D2 dopamine receptor coupling and modulate function
#140Therapy for subarachnoid hemorrhage and ischemia
#141Modified peptides as potent inhibitors of the PSD-95/NMDA receptor interaction
#142Mutant proteins and methods for their production
#143Compositions and methods for enhancing odorant receptor activity
#144Peptide inhibitors of nicotinic acetylcholine receptor
#145Method for selecting agents that bind to transmembrane receptors in a conformationally selective manner
#146Method of screening compounds for the treatment of diabetes
#147Peptide-based compounds and uses thereof to treat beta-amyloid accumulation
#148Agonistic autoantibodies to the alpha1-adrenergic receptor and the beta2-adrenergic receptor in Alzheimer's and vascular dementia
#149Photoreactive regulator of protein function and methods of use thereof
#150Cell line, system and method for optical control of secondary messengers
#151Method and composition for crystallizing G protein-coupled receptors
#152Modulation of activity of proneurotrophins
#153Compositions and methods for treating multiple sclerosis
#154Methods for screening for binding partners of G-protein coupled receptors
#155GPCR fusion protein containing an N-terminal autonomously folding stable domain, and crystals of the same
#156Binding domains directed against GPCR:G protein complexes and uses derived thereof
#157Method and composition for crystallizing G protein-coupled receptors
#158Vaccine for a therapeutic or a prophylactic treatment of myasthenia gravis
#159Polyethyleneimine And Beta2-Adrenergic Receptor Based Gene Therapy For Acute Lung Injury
#160Cell line, system and method for optical control of secondary messengers
#161NOGO receptor binding protein
#162Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity
#163Methods for modulating D1-D2 dopamine receptor coupling and function
#164Treating stroke and other diseases without inhibiting N-type calcium channels
#165Therapy for subarachnoid hemorrhage and ischemia
#166Photoreactive regulator of protein function and methods of use thereof
#167Method of identifying transmembrane protein-interacting compounds
#168Method for producing cAMP using chimeric olfactory receptor
#169METHOD AND SYSTEM FOR MAPPING SYNAPTIC CONNECTIVITY USING LIGHT MICROSCOPY
#170Compositions and methods for enhancing odorant receptor activity
#171EPITOPE TESTING USING SOLUBLE HLA
#172ANTI-HLA ASSAY AND METHODS
#173COMPARATIVE LIGAND MAPPING FROM MHC CLASS I POSITIVE CELLS
#174COMPARATIVE LIGAND MAPPING FROM MHC POSITIVE CELLS
#175Means for the inhibition of anti-β1-adrenergic receptor antibodies
#176Means for the inhibition of anti-beta1-adrenergic receptor antibodies
#177GPCR fusion protein containing an N-terminal autonomously folding stable domain, and crystals of the same
#178NOGO receptor binding protein
#179Cholinergic/serotoninergic receptor and uses thereof
#180Methods Relating to Peripheral Administration of Nogo Receptor Polypeptides
#181Photoreactive regulator of protein function and methods of use thereof
#182Caged Neuropeptides: modulation and measurement of synapse and signaling activity; and methods for drug evaluation, pharmaceuticals preparation and treatment
#183Method and composition for crystallizing G protein-coupled receptors
#184Polypeptides and methods for modulating D1-D2 dopamine receptor interaction and function
#185AUTOANTIBODY PRODUCTION INHIBITOR
#186Crystals of membrane proteins
#187Polypeptides that inhibit dopamine D2 receptor-DISC1 interaction and methods of use thereof
#188VECTORS FOR DELIVERY OF LIGHT SENSITIVE PROTEINS AND METHODS OF USE
#189Botulinum neurotoxin B receptors and use thereof
#190METHODS RELATING TO PERIPHERAL ADMINISTRATION OF NOGO RECEPTOR POLYPEPTIDES
#191Anticoagulant fusion protein anchored to cell membrane
#192Cytotoxic conjugates having neuropeptide Y receptor binding compound
#193Genetically engineered G-alpha proteins and uses thereof
#194Method and composition for crystallizing G protein-coupled receptors
#195Modified peptides as potent inhibitors of the PSD-95/NMDA receptor interaction
#196Method of modulating cell survival and reagents useful for same
#197Method and composition for crystallizing G protein-coupled receptors
#198Method and composition for crystallizing G protein-coupled receptors
#199HYBRID PROTEINS COMPRISING MEMBRANE RECEPTOR AND ION CHANNEL, AND THEIR USE AS BIOSENSORS
#200PEPTIDES WITH PROPERTIES OF AN ALLOSTERIC ANTAGONIST SELECTIVE FOR THE ALPHA 1A ADRENERGIC RECEPTOR AND USES THEREOF
#201Cell line, system and method for optical control of secondary messengers
#202CRYSTAL STRUCTURE
#203COMPOSITIONS AND METHODS FOR MODULATING NICOTINIC/NMDA RECEPTOR FUNCTION
#204Cannabinoid 2 (CB) receptor gene promoter and unique RNA transcripts in B cells and methods of use
#205EPITOPE TESTING USING SOLUBLE HLA
#206Mutant proteins and methods for selecting them
#207Excitatory glycine receptors and methods
#208NON-HUMAN MAMMAL MODEL OF EPILEPSY
#209Methods and compositions for obtaining high-resolution crystals of membrane proteins
#210Screening
#211Method and composition for crystallizing G protein-coupled receptors
#212CELL LINES EXPRESSING GABA RECEPTOR AND METHODS USING THEM
#213CELL LINES AND METHODS FOR MAKING AND USING THEM (As Amended)
#214Method of identifying transmembrane protein-interacting compounds
#215Nogo receptor-mediated blockade of axonal growth
#216Materials and methods for gene mediated therapy of psychiatric disorders
#217METHOD FOR PROLONGING LONGEVITY
#218Inhibitors of PDE4 and Methods of Use
#219Biosensors to measure InsP3 concentration in living cells
#220Modulation of activity of proneurotrophins
#221Compositions and methods for modulating AMPA receptor-mediated excitotoxicity
#222Nogo receptor binding protein
#223METHODS AND COMPOSITIONS FOR INVESTIGATION AND TREATMENT OF CANCER USING A G-PROTEIN COUPLED EICOSANOID RECEPTOR
#224Chimeric ligand-gated ion channels and methods of use thereof
#225PURIFICATION AND CHARACTERIZATION OF SOLUBLE MHC PROTEINS
#226Promoter variants of the alpha-7 nicotinic acetylcholine receptor
#227METHODS FOR MANIPULATING STEM CELLS
#228System and method for controlling G-protein coupled receptor pathways
#229Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability
#230Repression of AtGLR3.2 increases plant biomass
#231G-Protein Coupled Receptor and Uses Therefor
#232Botulinum neurotoxin a protein receptor and uses thereof
#233Polymorphisms and Haplotypes of the Alpha 2C Adrenergic Receptor Gene
#234PEPTIDES AGAINST AUTOANTIBODIES ASSOCIATED WITH GLAUCOMA AND USE OF THESE PEPTIDES
#235Means for the inhibition of anti-β1-adrenergic receptor antibodies
#236Y2 Selective Receptor Agonists for Therapeutic Interventions
#237Methods for removing anti-MHC antibodies from a sample
#238Tomoregulin-2-antibody compositions and methods for the diagnosis and treatment of Alzheimer's disease
#239Norepinepherine Transporter Mutants and Uses Thereof
#240Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity
#241CHOLINERGIC/SEROTONINERGIC RECEPTOR AND USES THEREOF
#242MOLECULES INVOLVED IN SYNAPTOGENESIS AND USES THEREFOR
#243Model animal of schizophrenia
#244Method and composition for crystallizing G protein-coupled receptors
#245Vaccine for a therapeutic or a prophylactic treatment of myasthenia gravis
#246PAR-4 RELATED METHODS AND COMPOSITIONS
#247TRANSGENIC MICE EXPRESSING HYPERSENSITIVE NICOTINIC RECEPTORS
#248Mutations in ion channels
#249Method of identifying transmembrane protein-interacting compounds
#250Methods and compositions for preventing and/or treating pancreatitis
#251Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
#252Composition and pharmacology of novel alpha6-containing nicotinic acetylcholine receptors
#253Tick octopamine receptor nucleic acid molecules
#254Genomic DNA fragments containing regulatory and coding sequences for the B2-subunit of the neuronal nicotinic acetylcholine receptor and transgenic animals made using these fragments or mutated fragments
#255TREATMENT OF CANCER WITH ANTI-MUSCARINIC RECEPTOR AGENTS
#256Role of alpha1-adrenergic receptors
#257Nanoscale Neuromodulating Platform For Retina Neuron Activation Apparatus and Method
#258Materials and methods relating to G-protein coupled receptor oligomers
#259Treating stroke and other diseases without inhibiting N-type calcium channels
#260Animal model, cells, and treatment for malignant melanoma
#261Y2/Y4 Selective Receptor Agonists for Therapeutic Interventions
#262Nogo receptor-mediated blockade of axonal growth
#263Trace amine receptor 1 of the african green monkey
#264Method of treating a muscle-related condition with modified IGF1 polypeptides
#265Novel proteins and nucleic acids encoding same
#266Canine 5-hydroxytryptamine 2A and 2B receptor
#267Human endothelin receptor
#268Mouse model of cholinergic dysfunction to evaluate cognitive enhancers and drugs that improve myasthenia
#269Grp Receptor-Related Methods for the Treating and Preventing Fear-Related Disorders
#270Inositol 1,4,5-Trisphosphate Receptor Mutants and Uses Thereof
#271CATION CONDUCTING GABAA RECEPTORS AND THEIR USE
#272Human Neuropeptide Receptor
#273Method of treating bladder and lower urinary tract syndromes
#274Process of high purity albumin production
#275Functional Screening Assay
#276RECOMBINANT FRAGMENTS OF THE HUMAN ACETYLCHOLINE RECEPTOR AND THEIR USE FOR TREATMENT OF MYASTHENIA GRAVIS
#277Molecules
#278Use of the receptor GPR86
#279Double mutant alpha-7 nicotinic acetylcholine receptor
#280Treatment of Cognitive Dysfunction in Lupus
#281Pain signaling molecules
#282Human neuronal nicotinic acetylcholine receptor compositions and methods employing same
#283FOGGY
#284Compositions capable of facilitation penetration across a biological barrier
#285Endogenous and non-endogenous version of human G protein-coupled receptors
#286TRANSCRIPTIONAL REGULATION OF THE HUMAN BETA3-ADRENERGIC RECEPTOR GENE
#287Photoreactive regulator of protein function and methods of use thereof
#288Diagnostic and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 7 (5-ht7)
#289SPLICE VARIANT CANNABINOID RECEPTOR (CB1B)
#290Materials and methods relating to G-protein coupled receptor oligomers
#291Comparative ligand mapping from MHC positive cells
#292Monkey npy y4 receptor and method of evaluating compound
#293Therapeutic agent for NGF
#294Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (seotonin) receptor 4 (5-ht4)
#295Nogo receptor binding protein
#296Rhesus monkey bombesin receptor subtype-3 (brs-3), nucleotides encoding same, and uses thereof
#297System for manipulating nucleic acids
#298G-protein coupled receptor and uses therefor
#299Immunogen, composition for immulogical use and process for producing antibody using the same
#300Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema